Clinical Trial Update: A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM) [Phase 1]

View source ↗

Summary

Phase 1 open-label study by Xencor to evaluate safety in healthy participants and those with idiopathic inflammatory myopathy; status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathies

Snippet

Sponsor: Xencor, Inc. | Conditions: Healthy, Idiopathic Inflammatory Myopathies | Phase 1 | Status: NOT_YET_RECRUITING